Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia (Q31804136)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 July 2017

Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 July 2017

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

author name string

Frost RJ

1

1 reference

Europe PubMed Central

PubMed publication ID

3 July 2017

Otto C

2

1 reference

Europe PubMed Central

PubMed publication ID

3 July 2017

Geiss HC

3

1 reference

Europe PubMed Central

PubMed publication ID

3 July 2017

Schwandt P

4

1 reference

Europe PubMed Central

PubMed publication ID

3 July 2017

Parhofer KG

5

1 reference

Europe PubMed Central

PubMed publication ID

3 July 2017

language of work or name

0 references

publication date

1 January 2001

1 reference

Europe PubMed Central

PubMed publication ID

3 July 2017

American Journal of Cardiology

1 reference

Europe PubMed Central

PubMed publication ID

3 July 2017

87

1 reference

Europe PubMed Central

PubMed publication ID

3 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

3 July 2017

44-48

1 reference

Europe PubMed Central

PubMed publication ID

3 July 2017

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901270-4

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901270-4

7 January 2021

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901270-4

7 January 2021

Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901270-4

7 January 2021

Clinical lipidology at the end of the millennium

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901270-4

7 January 2021

Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901270-4

7 January 2021

Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901270-4

7 January 2021

A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients witb hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901270-4

7 January 2021

Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901270-4

7 January 2021

Mechanism of action of fibrates on lipid and lipoprotein metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901270-4

7 January 2021

Fibrates, dyslipoproteinaemia and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901270-4

7 January 2021

Composition of human low density lipoprotein: effects of postprandial triglyceride-rich lipoproteins, lipoprotein lipase, hepatic lipase and cholesteryl ester transfer protein.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901270-4

7 January 2021

Statins do more than just lower cholesterol

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901270-4

7 January 2021

More on atorvastatin and fibrinogen

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901270-4

7 January 2021

Fenofibrate decreases plasma fibrinogen, improves lipid profile, and reduces uricemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901270-4

7 January 2021

Blood viscosity: influence of erythrocyte aggregation

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2901270-4

7 January 2021

Identifiers

10.1016/S0002-9149(00)01270-4

1 reference

Europe PubMed Central

PubMed publication ID

3 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q31804136&oldid=1542409605"